^
Association details:
| Biomarker: | ATM mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
631P - Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study
Published date:
09/13/2021
Excerpt:
These 2 responders had both a known HRD deleterious mutation (one BRCA2, one ATM). Disease control rate was 69.2% (18/26). Median radiographic PFS was 6.78 months (95% CI 4.28-9.01) and median OS 10.56 months (95% CI 6.68-NR)...Avelumab plus carboplatin has an acceptable safety profile. Overall clinical benefit was seen in almost 70% of patients and was associated with a prolonged OS given the heavily pretreated population.
Secondary therapy:
carboplatin
Source:
Title:
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Published date:
10/26/2022
Excerpt:
Safety and efficacy avelumab plus carboplatin was investigated in a single-arm Phase Ib study in mCRPC...Two of these responders had a known DDR alteration (one BRCA2, one ATM).
DOI:
https://doi.org/10.1038/s41416-022-01991-4
